FormWeb • insulin degludec-liraglutide

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search by class Show Therapeutic Classes

Add Formweb to your mobile device

Android iOS

Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

insulin degludec-liraglutide

insulin degludec-liraglutide

Non-formulary Insulin Formulary

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Xultophy	INJECTION, SUBCUTANEOUS	100 units/mL-3.6 mg/mL

Comments:

Non-formulary. Inpatients may use own supply. Defer initiation to after discharge.

Reviewed: 28 Nov 2017

REMS (Xultophy): View FDA REMS Info

Last updated: Feb. 3, 2025

Black Box Warning: Risk of Thyroid C-Cell Tumors
HAZ-MED: Table 2H (liraglutide)

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.